Hepatocyte Growth Factor
Recombinant proteinexperimental
Hepatocyte growth factor (HGF) or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration, and in wound healing. — Wikipedia
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Sep 1, 2005 (NCT00225901)
Timeline
Indications
Mechanism of action
- Hepatocyte growth factorSupplementation
HGF supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHepatocyte growth factor ↗
Also known as
- hepatocyte growth factor
- hgf
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05627648 | Phase 3 | Nov 18, 2022 | Kringle Pharma, Inc. |
| NCT04475224 | Phase 3 | Jul 13, 2020 | Kringle Pharma, Inc. |
| NCT02193334 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2014 | Kringle Pharma, Inc. |
| NCT00225901 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2005 | Kyoto University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kringle Pharma, Inc. | For profit | 3 | 3 | 2 | 2014 |
| Kyoto University | Academic/Hospital | 1 | 1 | 1 | 2005 |
2 organizations
Page 1 / 1